Procyrion,
Inc.

A 28-person company in a nineteen-year sprint

Procyrion is a medical device company in Houston, Texas, with roughly two-dozen-and-change employees and exactly one product that matters: Aortix. By the usual startup math, a company this old with this few people and no revenue should be a cautionary tale. By the math of cardiac devices - where a single approval can take fifteen years and a billion dollars - it is precisely on schedule.

The company sits inside the Texas Medical Center, the largest medical complex in the world, which is a convenient address for a firm whose entire premise was born across the street. Today its focus is narrow and unglamorous: get Aortix through a pivotal FDA trial and into the hands of cardiologists treating the patients nobody else has a good answer for.

When the heart fails, it takes the kidneys down with it

Here is the cruel loop at the center of Procyrion's existence. A weak heart pumps less blood. The kidneys, starved of flow, stop clearing fluid. That retained fluid floods back toward the heart, which now has even more to push against, so it weakens further. Doctors call it cardiorenal syndrome. Patients call it drowning slowly. Some are carrying 30 or 40 pounds of extra fluid by the time they reach a hospital.

The standard tool is a high dose of IV diuretics - drugs that tell the kidneys to dump fluid. The problem, with the dark humor the body reserves for these things, is that the kidneys most in need of help are exactly the ones too starved to respond. The drugs stop working. And the surgical heart pumps that could help, like LVADs, require an operation these patients are often too fragile to survive.

So there is a gap. On one side, a pill that has quit. On the other, a surgery too big to attempt. Into that gap, Procyrion pointed a catheter.

A cardiologist with an idea he couldn't shake

The bet started with Reynolds Delgado III, a heart-failure cardiologist who ran mechanical circulatory support at the Texas Heart Institute. He kept watching the same patients cycle through, fluid-logged and out of options, and kept asking a stubborn question: what if a pump didn't have to live inside the heart at all? What if it sat downstream, in the aorta, and simply helped move things along?

That question became Procyrion around 2005. It was, by any honest accounting, an inconvenient idea - the kind that requires two decades and five funding rounds to prove. Delgado stayed on as Chief Medical Officer rather than chasing the title that usually goes to founders, which tells you something about where his interest actually was.

The other half of the bet arrived later, in the form of a CEO who didn't need the job. Eric Fain had run cardiovascular and neuromodulation at Abbott, one of the largest device makers on earth. He left it to lead a company a fraction of a percent of that size. People don't usually do that for the equity. They do it for the device.

Aortix doesn't push blood. It pulls it

Most catheter heart pumps - the famous one is Abiomed's Impella - work by crossing the aortic valve and pumping blood out of the left ventricle directly. Effective, but it means parking hardware across one of the body's busiest doorways. Aortix takes a different route. It anchors in the descending aorta, well past the valve, and uses what engineers call jet entrainment: tiny high-velocity jets of blood that drag the surrounding blood along with them, the way a fast river pulls slower water at its edges.

The effect is two things at once, which is the whole point. By pulling blood forward, Aortix reduces the pressure the heart has to pump against - it unloads the heart. And by accelerating flow downstream toward the kidneys, it restores the renal perfusion that the failing heart took away. One small pump, aimed squarely at both ends of the cardiorenal loop.

Money is a vote. Trials are the verdict

Belief in medtech is denominated in two currencies: capital and clinical data. On the capital side, Procyrion has raised somewhere north of $110 million across its named rounds, the largest being the $57.7 million Series E that closed in February 2024. The lead investor, Fannin Partners, has been there since the seed - a vote of confidence that has now lasted longer than most marriages.

But money only buys the chance to find out. The verdict is DRAIN-HF, the pivotal IDE trial that began enrolling in late 2023. It aims to enroll up to 268 patients across roughly 45 US centers, comparing Aortix head-to-head against the standard of high-dose diuretics. If the data holds, it becomes the basis for FDA approval. If it doesn't, nineteen years meets the wall every device eventually meets. That is the tension this entire company is built around, and it is not yet resolved.

One unmet need, treated seriously

Procyrion's stated mission is plain enough to be easy to underestimate: address the unmet clinical needs of heart-failure patients through a safe percutaneous mechanical circulatory support device. No talk of disruption, no promise to reinvent cardiology. Just one population - the diuretic-resistant, the fluid-overloaded, the too-sick-for-surgery - and a device built from the ground up for them.

It helps that the team is mostly engineers and cardiologists rather than marketers. A company that recognizable from its product alone tends to have its priorities in the right order. The recognition has followed: a spot on Fierce Medtech's Fierce 15 of 2023, the industry's annual shortlist of the device startups worth watching.

If it works, the gap closes

Heart failure affects millions, and the cardiorenal subset is among the hardest to treat and most expensive to readmit. A minimally invasive device that breaks the heart-kidney loop without surgery wouldn't just be a new product line. It would be a new option in a place where, today, doctors mostly run out of them. That is the bet. We will know if it paid off when DRAIN-HF reads out.

Back in that cath lab, the catheter comes out and the pump is in place. The patient who arrived drowning in their own fluid starts, within hours, to produce urine again - sometimes for the first time in days. That is the scene Procyrion has spent nineteen years trying to make ordinary. Whether it becomes ordinary depends on a few hundred patients and one trial. The pump is the size of a pencil. The question it is trying to answer is not.